ArticlePloS one2019

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.

Saara Huoponen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.